FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319985497> ?p ?o ?g. }

• W4319985497 abstract "There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based).A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and ≥ 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy.The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0-14.0) months in the ET arm of group A, and 5.3 (3.9-6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8-7.7) months in the ET arm of group B, and 5.7 (4.6-6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5-8.0) months in the ET arm of group C and 4.0 (3.5-4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months.Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET." @default.
• W4319985497 created "2023-02-11" @default.
• W4319985497 creator A5000010091 @default.
• W4319985497 creator A5000035599 @default.
• W4319985497 creator A5001909426 @default.
• W4319985497 creator A5002010642 @default.
• W4319985497 creator A5002622942 @default.
• W4319985497 creator A5004225132 @default.
• W4319985497 creator A5004317421 @default.
• W4319985497 creator A5005309444 @default.
• W4319985497 creator A5008382382 @default.
• W4319985497 creator A5009438753 @default.
• W4319985497 creator A5009794849 @default.
• W4319985497 creator A5011031533 @default.
• W4319985497 creator A5012491910 @default.
• W4319985497 creator A5014774154 @default.
• W4319985497 creator A5014804922 @default.
• W4319985497 creator A5014818385 @default.
• W4319985497 creator A5015596191 @default.
• W4319985497 creator A5015745342 @default.
• W4319985497 creator A5015870380 @default.
• W4319985497 creator A5016651192 @default.
• W4319985497 creator A5019277255 @default.
• W4319985497 creator A5019649792 @default.
• W4319985497 creator A5021534303 @default.
• W4319985497 creator A5021654304 @default.
• W4319985497 creator A5022918510 @default.
• W4319985497 creator A5023017548 @default.
• W4319985497 creator A5024635558 @default.
• W4319985497 creator A5026761225 @default.
• W4319985497 creator A5027251875 @default.
• W4319985497 creator A5028570951 @default.
• W4319985497 creator A5030033078 @default.
• W4319985497 creator A5030107749 @default.
• W4319985497 creator A5030982886 @default.
• W4319985497 creator A5031289065 @default.
• W4319985497 creator A5031299541 @default.
• W4319985497 creator A5032213709 @default.
• W4319985497 creator A5035460759 @default.
• W4319985497 creator A5040602975 @default.
• W4319985497 creator A5041705584 @default.
• W4319985497 creator A5042914606 @default.
• W4319985497 creator A5043803426 @default.
• W4319985497 creator A5044732985 @default.
• W4319985497 creator A5045255203 @default.
• W4319985497 creator A5050192409 @default.
• W4319985497 creator A5050241263 @default.
• W4319985497 creator A5051032664 @default.
• W4319985497 creator A5051408219 @default.
• W4319985497 creator A5051591826 @default.
• W4319985497 creator A5052112651 @default.
• W4319985497 creator A5052565005 @default.
• W4319985497 creator A5052748672 @default.
• W4319985497 creator A5054602049 @default.
• W4319985497 creator A5057432590 @default.
• W4319985497 creator A5057475586 @default.
• W4319985497 creator A5058277753 @default.
• W4319985497 creator A5058897783 @default.
• W4319985497 creator A5059941445 @default.
• W4319985497 creator A5061048010 @default.
• W4319985497 creator A5061674757 @default.
• W4319985497 creator A5063093037 @default.
• W4319985497 creator A5063142015 @default.
• W4319985497 creator A5064417858 @default.
• W4319985497 creator A5064627647 @default.
• W4319985497 creator A5065597755 @default.
• W4319985497 creator A5065621918 @default.
• W4319985497 creator A5065673888 @default.
• W4319985497 creator A5068641307 @default.
• W4319985497 creator A5069536993 @default.
• W4319985497 creator A5069716603 @default.
• W4319985497 creator A5070024016 @default.
• W4319985497 creator A5071738025 @default.
• W4319985497 creator A5071962635 @default.
• W4319985497 creator A5075291709 @default.
• W4319985497 creator A5075689301 @default.
• W4319985497 creator A5078894207 @default.
• W4319985497 creator A5078899307 @default.
• W4319985497 creator A5079931964 @default.
• W4319985497 creator A5081243615 @default.
• W4319985497 creator A5081409201 @default.
• W4319985497 creator A5081883458 @default.
• W4319985497 creator A5081990284 @default.
• W4319985497 creator A5084377322 @default.
• W4319985497 creator A5086059674 @default.
• W4319985497 creator A5087558124 @default.
• W4319985497 creator A5089035885 @default.
• W4319985497 creator A5091450173 @default.
• W4319985497 date "2023-02-10" @default.
• W4319985497 modified "2023-10-17" @default.
• W4319985497 title "Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy" @default.
• W4319985497 cites W2134466276 @default.
• W4319985497 cites W2167188058 @default.
• W4319985497 cites W2528767298 @default.
• W4319985497 cites W2552099557 @default.
• W4319985497 cites W2891975996 @default.
• W4319985497 cites W2916875993 @default.
• W4319985497 cites W2947984984 @default.
• W4319985497 cites W3045133340 @default.
• W4319985497 cites W3093844978 @default.

• next